220: The last-minute push for drug pricing reform, Alnylam's success, and Sarepta's gamble

Is drug pricing reform really happening this time? Are things finally turning around for biotech? And is it ever wise to tweet your food? Rachel Cohrs, STAT's Washington correspondent, joins us to explain how congressional Democrats are on the verge of a coup in drug pricing — and what could still stand in their way. We also discuss the latest news in the life sciences, including some hotly anticipated data from Alnylam Pharmaceuticals, a $4 billion buyout deal, and other surprisingly good news for biotech.